Medibank Private (MPL) Stock Overview
Provides private health insurance in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
MPL Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Medibank Private Limited. Quality Business With No Margin Of Safety!
View narrative
Medibank Private Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.62 |
| 52 Week High | AU$5.31 |
| 52 Week Low | AU$4.06 |
| Beta | 0.046 |
| 1 Month Change | -8.51% |
| 3 Month Change | -5.71% |
| 1 Year Change | -4.74% |
| 3 Year Change | 32.76% |
| 5 Year Change | 31.25% |
| Change since IPO | 115.89% |
Recent News & Updates
Medibank Private Limited. Quality Business With No Margin Of Safety!
Price A$5.00 · Mkt cap ~A$13.8bn · as of 6 Jul 2026 · FY ends 30 June · 52-wk A$4.10–5.26 · AUD Franchise Score: 15 / 22 Rating: High-B Deep-value (operative): WATCH Compounder: WATCH Operative call: WATCH at A$5.00 — a genuinely high-quality, net-cash, #1-share regulated oligopolist, but priced for its quality (≈22× forward underlying EPS, ~30× statutory, 5.9× book, 7.5× tangible book) with no margin of safety and negligible asset floor. The compounder lens also reads WATCH (flat-multiple owner return ~8% cash / ~10% grossed-up, below the 12–15% hurdle).
MPL: Future Margins And P/E Assumptions Point To Fairly Balanced Outlook
Analysts have slightly reduced their Medibank Private price target to A$5.03, reflecting updated assumptions around discount rates, margins and future P/E multiples, while keeping the overall narrative broadly unchanged. What's in the News There are currently no recent Medibank Private specific news items provided in the source set, so price target changes are being assessed primarily against internal analyst assumptions rather than new company announcements.Recent updates
Medibank Private Limited. Quality Business With No Margin Of Safety!
Price A$5.00 · Mkt cap ~A$13.8bn · as of 6 Jul 2026 · FY ends 30 June · 52-wk A$4.10–5.26 · AUD Franchise Score: 15 / 22 Rating: High-B Deep-value (operative): WATCH Compounder: WATCH Operative call: WATCH at A$5.00 — a genuinely high-quality, net-cash, #1-share regulated oligopolist, but priced for its quality (≈22× forward underlying EPS, ~30× statutory, 5.9× book, 7.5× tangible book) with no margin of safety and negligible asset floor. The compounder lens also reads WATCH (flat-multiple owner return ~8% cash / ~10% grossed-up, below the 12–15% hurdle).MPL: Future Margins And P/E Assumptions Point To Fairly Balanced Outlook
Analysts have slightly reduced their Medibank Private price target to A$5.03, reflecting updated assumptions around discount rates, margins and future P/E multiples, while keeping the overall narrative broadly unchanged. What's in the News There are currently no recent Medibank Private specific news items provided in the source set, so price target changes are being assessed primarily against internal analyst assumptions rather than new company announcements.MPL: Fair Value Update Balances Margin Resilience With Digital Health Risks
Narrative Update Analysts have nudged their Medibank Private fair value estimate higher to A$5.16 from A$5.08. This reflects updated assumptions for slightly stronger revenue growth and profit margins, partly balanced by a higher discount rate and a modestly lower future P/E multiple.Some Shareholders Feeling Restless Over Medibank Private Limited's (ASX:MPL) P/E Ratio
Medibank Private Limited's ( ASX:MPL ) price-to-earnings (or "P/E") ratio of 26.5x might make it look like a sell right...Earnings Not Telling The Story For Medibank Private Limited (ASX:MPL)
Medibank Private Limited's ( ASX:MPL ) price-to-earnings (or "P/E") ratio of 26.2x might make it look like a sell right...Will Invest Up To $250 Million In Healthcare Acquisitions To Augment Market Presence
The consensus analyst price target for Medibank Private has increased to A$5.05, primarily reflecting improved revenue growth forecasts despite a slight decline in net profit margin. Valuation Changes Summary of Valuation Changes for Medibank Private The Consensus Analyst Price Target has risen slightly from A$4.95 to A$5.05.
Myhealth Expansion Will Drive Future Customer Retention
Expansion in primary care and strategic investments are set to drive long-term revenue and profit growth.Shareholder Returns
| MPL | AU Insurance | AU Market | |
|---|---|---|---|
| 7D | 1.5% | 3.5% | -2.9% |
| 1Y | -4.7% | -2.2% | -3.7% |
Return vs Industry: MPL underperformed the Australian Insurance industry which returned -2.2% over the past year.
Return vs Market: MPL underperformed the Australian Market which returned -3.7% over the past year.
Price Volatility
| MPL volatility | |
|---|---|
| MPL Average Weekly Movement | 3.2% |
| Insurance Industry Average Movement | 3.8% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 16.5% |
| 10% least volatile stocks in AU Market | 3.8% |
Stable Share Price: MPL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MPL's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5,001 | David Koczkar | www.medibank.com.au |
Medibank Private Limited provides private health insurance in Australia. The company operates in two segments, Health Insurance and Medibank Health. The Health Insurance segment provides private health insurance products, including hospital cover that offers members with health cover for hospital treatments; and ancillary cover, which provides members with health cover for healthcare services comprising dental, optical, and physiotherapy, as well as offers health insurance products to overseas visitors and students.
Medibank Private Limited Fundamentals Summary
| MPL fundamental statistics | |
|---|---|
| Market cap | AU$12.92b |
| Earnings (TTM) | AU$638.70m |
| Revenue (TTM) | AU$9.30b |
Is MPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MPL income statement (TTM) | |
|---|---|
| Revenue | AU$9.30b |
| Cost of Revenue | AU$7.03b |
| Gross Profit | AU$2.26b |
| Other Expenses | AU$1.62b |
| Earnings | AU$638.70m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 24.34% |
| Net Profit Margin | 6.87% |
| Debt/Equity Ratio | 1.5% |
How did MPL perform over the long term?
See historical performance and comparisonDividends
Does MPL pay a reliable dividends?
See MPL dividend history and benchmarks| Medibank Private dividend dates | |
|---|---|
| Ex Dividend Date | Sep 02 2026 |
| Dividend Pay Date | Oct 08 2026 |
| Days until Ex dividend | 15 days |
| Days until Dividend pay date | 21 days |
Does MPL pay a reliable dividends?
See MPL dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 16:22 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medibank Private Limited is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Adams | Barrenjoey Markets Pty Limited |
| John Hester | Bell Potter |
| Freya Kong | BofA Global Research |